Last reviewed · How we verify
NCT03792919
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
Phase 4 trial testing Stop current treatment (anti-HBV neucleos(t)ides) in Chronic Hepatitis B in 2,000 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Humanity & Health Medical Group Limited |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2,000 |
| Start date | 1 December 2018 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Stop current treatment (anti-HBV neucleos(t)ides) — full drug profile →
- Keep current treatment (anti-HBV neucleos(t)ides) — full drug profile →
Conditions studied
- Chronic Hepatitis B — all drugs for Chronic Hepatitis B →
Sponsor
Humanity & Health Medical Group Limited — full company profile →
Who can join
Eligibility, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03792919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Hepatitis B
Currently open trials in the same condition.
- NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
- NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
- NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
- NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
- NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting
Other Humanity & Health Medical Group Limited trials
Trials by the same sponsor.
- NCT05470894 — Liver Injury After COVID-19 Vaccination · completed
- NCT04428437 — Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors · terminated
- NCT04775069 — Antibody Response to COVID-19 Vaccines in Liver Disease Patients · Phase 4 · completed
- NCT03899428 — Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC · Phase 2 · recruiting
- NCT03794258 — Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03792919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Humanity & Health Medical Group Limited
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03792919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing